Market Overview

UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance

Share:
Related CRL
Jefferies Boosts Targets Across Pharmaceutical Service Stocks
Benzinga's Top Upgrades
Carl Appoints Rick Sanderson to the Board of Directors (GuruFocus)

ISI Group reiterated its Underweight rating on Charles River Laboratories (NYSE: CRL) and lowered its price target from $40.50 to $39.

ISI Group commented, "As a result of today's 2013 guidance announcement, we are lowering CRL's FY13 EPS from $3.10 to $3.00 and FY14 EPS from $3.45 to $3.25. These EPS changes stem from lower operating margin expectations due to the aforementioned investment headwinds. Despite the improved revenue outlook, limited visibility across the business (ex strategic deals) and a challenged OM outlook will limit P/E expansion, and in turn, cap shares in the upper $30s."

Charles River Laboratories closed at $36.55 on Tuesday.

Latest Ratings for CRL

DateFirmActionFromTo
May 2015Edward JonesUpgradesNeutralBuy
Apr 2015BarclaysMaintainsEqual-weight
Apr 2015JefferiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CRL)

Around the Web, We're Loving...

Get Benzinga's Newsletters